Inhibition of Collagenase by Mycosporine-like Amino Acids from Marine Sources

Authors

Anja Hartmann¹, Johanna Gostner², Julian E. Fuchs³, Eliza Chaita⁴, Nektarios Aligiannis⁴, Leandros Skaltsounis⁴, Markus Ganzera¹

Affiliations

¹ Institute of Pharmacy, Pharmacognosy, University of Innsbruck, Innsbruck, Austria

² Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria

³ Center for Molecular Informatics, Department of Chemistry, University of Cambridge, Cambridge, United Kingdom

⁴ Department of Pharmacognosy and Natural Products Chemistry, Faculty of Pharmacy, University of Athens, Athens, Greece

Key words

- collagenase
- mycosporine-like amino acids
- algae
- skin aging

Abstract

Matrix metalloproteinases play an important role in extracellular matrix remodeling. Excessive activity of these enzymes can be induced by UV light and leads to skin damage, a process known as photoaging. In this study, we investigated the collagenase inhibition potential of mycosporine-like amino acids, compounds that have been isolated from marine organisms and are known photoprotectants against UV-A and UV-B. For this purpose, the commonly used collagenase assay was optimized and for the first time validated in terms of relationships between enzyme-substrate concentrations, temperature, incubation time,

and enzyme stability. Three compounds were isolated from the marine red algae *Porphyra* sp. and *Palmaria palmata*, and evaluated for their inhibitory properties against *Chlostridium histolyticum* collagenase. A dose-dependent, but very moderate, inhibition was observed for all substances and IC₅₀ values of 104.0 μM for shinorine, 105.9 μM for porphyra, and 158.9 μM for palythine were determined. Additionally, computer-aided docking models suggested that the mycosporine-like amino acids binding to the active site of the enzyme is a competitive inhibition.

Supporting information available online at <http://www.thieme-connect.de/products>

Introduction

Collagen is the major structural protein in human skin. Consisting of a triple helix scaffold, the tensile strength of its fibers provide structural support for bones, skin, tendons, ligaments, and blood vessels, and are responsible for a dynamic strength of the skin. Mature dermal collagen is formed from precursor molecules called procollagens [1]. Collagenases, which belong to the family of matrix metalloproteinases (MMPs), are transmembrane zinc endopeptidase enzymes. By digesting collagen and elastin fibers, they play important roles in many processes including tissue remodeling during development, tissue homeostasis, and repair after wounding [2]. However, an over activation due to photoaging and chronic aging leads to alterations in the collagen and elastin composition of the extracellular matrix (ECM) and results in wrinkles, laxity, sagging, and a coarse appearance of the human skin [3,4]. The upregulation of certain MMPs has been shown to promote cancer progression and to induce angiogenesis by two modes. First, by activating growth factors such as the transforming

growth factor beta (TGF-β) and the vascular endothelial growth factor (VEGF) and second, by degrading the ECM and E-cadherin molecules, which are important to maintain intercellular interactions [5]. Activity of these enzymes can also be pathologically upregulated in response to UV light exposure (photodamage) or the release of reactive oxygen species (ROS). In addition, *in vivo* studies prove that UV irradiation results in a reduction of procollagen synthesis [3–5]. Several authors have reported that upregulated MMPs and diminished procollagen synthesis are mechanisms involved in natural skin aging [6,7]. On the contrary, Chung et al. [8] considered a reduced collagen production and a rise in MMP levels typical for naturally aged skin, while in photoaged skin both parameters tend to be enhanced. The observed effect results in collagen depletion due to the much higher amount of MMP.

The discovery of new substances that can prevent connective tissue damage is of great interest for the pharmaceutical and cosmetic industries, and many studies about matrix-metalloproteinase inhibitors from higher plants can be found in the literature [9–11]. Marine organisms are interesting

received January 21, 2015
revised April 14, 2015
accepted April 19, 2015

Bibliography

DOI <http://dx.doi.org/10.1055/s-0035-1546105>
Published online June 3, 2015
Planta Med 2015; 81: 813–820
© Georg Thieme Verlag KG
Stuttgart · New York ·
ISSN 0032-0943

Correspondence

Assoc. Prof. Dr. Markus Ganzera

Institute of Pharmacy,
Pharmacognosy
University of Innsbruck
Innrain 80–82
6020 Innsbruck
Austria
Phone: +43 5 1250 75 84 06
Fax: +43 5 1250 75 84 99
markus.ganzera@uibk.ac.at

Fig. 1 Michaelis-Menten equation performed with eight different MMP-2 fluorogenic substrate concentrations ranging from 4.17 to 166.67 $\mu\text{g/mL}$ (initial conc.); enzyme: 100 $\mu\text{g/mL}$ (initial conc.). (Color figure available online only.)

Fig. 2 Lineweaver-Burk plot resulting in a K_m of 51.7 μM (12.9 μM final). This was done in order to determine the initial substrate concentration required for a consistent reaction. (Color figure available online only.)

sources for new active biomolecules, as they are known to produce potent photoprotective metabolites for their defense. To date, only a few studies support the collagenase inhibition potential of natural products isolated from marine algae. Among the compounds tested so far, oligosaccharides, marine polyphenols, and fatty acids have been found to inhibit MMP-2 and MMP-9 [12]. However, to the best of our knowledge, this is the first study that investigates mycosporine-like amino acids (MAAs) for their collagenase inhibition potential. In addition, no marine substance has been tested on bacterial collagenase (chlostridiopeptidase A). The investigated compounds were isolated from marine red algae and assayed for their inhibitory potential against microbial collagenase from *Clostridium histolyticum*. Molecular modeling was used to depict potential interactions between the isolated compounds and the enzyme. Furthermore, we validated and optimized the anti-collagenase assay for high-throughput screening (HTS) purposes.

Results

Assay optimization was initiated by the evaluation of the optimal enzyme to substrate ratio. This was necessary because a broad range of different substrate and enzyme concentrations is described in the literature. Moreover, those assays vary in the types

of substrates and enzymes and none of these previously conducted assays has been validated, which makes a comparison of generated data rather difficult. Therefore, optimization was set by testing different enzyme concentrations, ranging from 400 $\mu\text{g/mL}$ to 40 $\mu\text{g/mL}$ (initial concentration), resulting in an optimum concentration of 100 $\mu\text{g/mL}$ (initial), which showed a suitable ratio of enzyme activity. To optimize the substrate concentration, the Michaelis-Menten constant (K_m) and the maximum velocity ($V_{\max}$) were determined by measuring the velocity of MMP-2 fluorogenic substrate conversion in a concentration range from 4.17 $\mu\text{g/mL}$ to 166.67 $\mu\text{g/mL}$ (initial concentrations; **Fig. 1**). The values for K_m (51.67 μM) and $V_{\max}$ 212.76 $\mu\text{mol/min}$ were obtained by linear regression of the Michaelis-Menten curve (Lineweaver-Burk plot), as shown in **Fig. 2**. As the enzyme constantly cleaves the substrate, the concentration of the latter is diminished during the assay, resulting in increasing nonlinearity of the reaction when $[S] \ll K_m$ [13]. Therefore, the optimum substrate concentration was chosen around the determined value of K_m . A final substrate concentration of 13.89 $\mu\text{g/mL}$ was used in all experiments. The established ratio of approximately one part of enzyme (100 $\mu\text{g/mL}$) to two parts of substrate (55.55 $\mu\text{g/mL}$) showed a stable reaction performance, as indicated by a linear curve over more than 30 min of the reaction time (**Fig. 3**). Longer reaction times resulted in trending slightly to a maximum. In a next step, the optimal reaction temperature was assessed by

Fig. 3 Confirmation of a linear and time-dependent cleavage of the substrate under optimized assay conditions; 0–30 min: linear conditions; 0–45 min: a longer assay duration leads to nonlinearity.

performing the assay at room temperature (RT), 30 °C, and 37 °C and by using the standard inhibitor phosphoramidon at an initial concentration of 50 µg/mL. For 30 °C and 37 °C reaction temperature, the same inhibition rate of 53.4% was obtained, while at RT, the inhibition was only slightly decreased (49.1%). This indicates that in case thermo-labile substances are tested, the assay could also be carried out at temperatures around 25 °C. For MAAs this was not required, thus the incubation time was evaluated at 37 °C. The optimum incubation time of inhibitor-enzyme reactions was also investigated. No measurable differences were observed in the inhibition rate of phosphoramidon whether the incubation time was set to 5, 10, or 15 min. Longer incubation times, however, resulted in lower rates of enzyme inhibition; for example, an incubation time of 20 min resulted in a 10% lower inhibitory capacity compared to that of 15 min. The utilized collagenase was stable in a concentration of 1 mg/mL when kept on ice for up to 6 h. Finally, assay validation was carried out with phosphoramidon and 1,10-phenanthroline, two standard inhibitors reported in the literature [14–16]. Incubation was carried out at 37 °C for 10 min, and the reaction was monitored over 30 min. The tested concentration range for phosphoramidon was from 0.78 to 62.5 µg/mL (final concentration). An IC_{50} of $18.8 \mu\text{M} \pm 1.6$ ($11.07 \mu\text{g/mL} \pm 1.30$) was determined for phosphoramidon (Mr 587.47). The concentration range for the second standard inhibitor 1,10-phenanthroline (Mr 180.21) ranged from 6.25 to 250 µg/mL, and the IC_{50} value was calculated to be $238.1 \mu\text{M} \pm 3.4$ ($42.86 \mu\text{g/mL} \pm 1.35$). This result does not indicate a significant or physiologically relevant inhibition, but the value is in accordance with the literature [16].

Method validation was carried out via the endpoint reading mode and kinetic mode. For the latter, fluorescence was measured every 5 min over a total assay period of 30 min. The area under the curve (AUC) was calculated for seven different concentrations for the standard inhibitor phosphoramidon (serial dilution steps). For each approach, the IC_{50} of phosphoramidon was calculated (● Fig. 4). In addition, the limit of quantification (LOQ) and limit of detection (LOD) were determined. ● Table 1 compares the two different approaches of data analysis. As can be seen, both ways of data evaluation are comparable to each other. Validation results are slightly better in the endpoint reading mode and are more useful for high-throughput screening purposes. However, the kinetic reading mode shows a consistent evaluation of inhibition based on a given time frame and not only in terms of a value of fluorescent units at a certain point in time.

NMR data of the isolated compounds and their stereochemistry were in agreement with the literature [17,18]. Palythine, porphyra, and shinorine are based on the same cyclohexenimine structure, and the amino acid, which is conjugated to the ring system in position 3, is always glycine (● Fig. 5).

The isolated substances were tested using the fully validated procedure described above. The IC_{50} values for palythine and shinorine were evaluated using eight serial dilutions in a concentration range from 12.5 to 125 µg/mL (final concentration). The IC_{50} value of palythine was found to be $158.9 \mu\text{M} \pm 3.2$ ($38.82 \mu\text{g/mL} \pm 0.78$), and that of shinorine was $104.0 \mu\text{M} \pm 3.7$ ($34.42 \mu\text{g/mL} \pm 1.23$). Porphyra was diluted in a concentration range from 1.87 to 150 µg/mL, and an IC_{50} value of $105.9 \mu\text{M} \pm 2.3$ ($37.73 \mu\text{g/mL} \pm 1.95$) was calculated. The three MAAs showed a moderate inhibition of collagenase (● Table 2), even the determined values were lower than for 1,10-phenanthroline ($238.1 \mu\text{M} \pm 3.4$; $42.86 \mu\text{g/mL} \pm 1.35$), a standard inhibitor for collagenase described in the literature (70.4 µg/mL) [16]. The results are comparable to inhibitors found in higher plants such as ecdysteroids, with IC_{50} values from 28–50 µg/mL [16]. Others, like (+) catechin-aldehyde polycondensates (IC_{50} values from 200 to 350 µM; [14]) and epigallocatechingallate ($IC_{50} = 114 \mu\text{g/mL}$; [15]), are less active than the investigated MAAs. No marine species or substances have been tested on bacterial collagenase (clostridiopeptidase A) so far. Yet, a small number of substances, like marine saccharides (chitooligosaccharides), glycosaminoglycan from *L. vannamei*, flavonoids, and fatty acids from a marine source, have been investigated for their MMP-2 (gelatinase A, collagenase type IV) and MMP-9 (gelatinase B; type IV precursor collagenase) inhibition in cell lines [19].

To rationalize collagenase inhibition on a structural level, we performed *in silico* docking studies for porphyra, palythine, and shinorine to the crystal structure of collagenase G from *C. histolyticum* (PDB: 2Y6I) [20]. We generated the protein structure using protonate3d [21] and ionized the MAAs for neutral pH in MOE (Molecular Operating Environment MOE 2014.09; Chemical Computing Group, Inc.). Water molecules coordinating the active site Zn^{2+} ion were preserved to mimic the peptide-bound state resolved in the crystal structure with observed docking results. We used MOE's default settings for flexible docking including placement by Triangle Matcher, scoring by London dG, a force-field refinement of 30 intermediate poses, and rescoring by GBVI/WSA dG. We introduced additional pharmacophore constraints during docking, enforcing an acidic group coordinating

Fig. 4 IC₅₀ value of the standard inhibitor phosphoramidon as determined by the endpoint reading (A) or calculated based on the AUC from 0 to 30 min (B); n = 3.

Parameter	Endpoint reading mode	Kinetic reading mode (AUC)
Linearity	1) $Y = -1400 \ln x + 8932.2$, $R^2 = 0.9936$ 2) $Y = -1512 \ln x + 9152.2$, $R^2 = 0.9957$ 3) $Y = -1183 \ln x + 8503.3$, $R^2 = 0.9913$	1) $Y = -657.3 \ln x + 3883.0$, $R^2 = 0.9906$ 2) $Y = -639 \ln x + 3812.6$, $R^2 = 0.9991$ 3) $Y = -923.5 \ln x + 5066.1$, $R^2 = 0.9869$
IC ₅₀	11.07 μg/mL ± 0.95	11.95 μg/mL ± 1.28
Linear range	62.5–0.78 μg/mL	62.5–0.78 μg/mL
LOD/LOQ	LOD: 1.14 μg/mL LOQ: 3.47 μg/mL	LOD: 2.45 μg/mL LOQ: 7.43 μg/mL

Table 1 Comparison of the endpoint reading mode at 30 min vs. the kinetic reading mode (0–30 min) using the standard inhibitor phosphoramidon as an example (n = 3).

to the Zn²⁺ ion as well as a hydrophobic group in the S2 pocket, thus replacing the proline side chain in the native peptide position P2'. Resulting complexes were visualized using the software package Pymol (version 1.5.0.2) [22]. Poses are shown in **Fig. 6**, and docking scores are given as Supplementary Information. The three investigated MAAs are predicted to occupy a similar region within the binding site of the collagenase that overlaps with the native peptide's P1'–P3' region. The Zn²⁺ ion is consistently bound to the carboxylate group of the glycine substructure in the MAA, replacing the native P1' glycine residue. This nicely

matches the strong preference of collagenases for small amino acids at the P1' position [23,24]. The MAA's hydrophobic rings occupy the position of the P2' proline, again matching collagenases' preferences for this particular amino acid. The larger MAAs shinorine and porphyrin stretch further towards the S3' pocket. As all MAAs are predicted to occupy the catalytic center of collagenase, a competitive binding mode would be expected, whereby the compounds are expected to inhibit the enzyme due to direct coordination to its active site.

Fig. 5 Chemical structures of porphyra (I), shinorine (II), and palythine (III).

Discussion

A number of collagenase inhibitors isolated from higher plants are described in the literature, belonging to different compound classes like flavonoids [25,26], catechins [27], polyphenols (e.g., resveratrol) [28,29], or steroids [16]. Also, several multicomponent extracts were reported to inhibit collagenase activity [15]. Only a few attempts were made to utilize marine algae as a source for potential collagenase inhibitors, although these organisms are enormously rich in bioactive compounds that are produced in response to UV light. This includes MAAs, which derive from the shikimic acid pathway with 4-desoxygadusol as a direct precursor molecule. The latter is known to be a strong antioxidant [30]. MAAs also act as ROS scavengers after UV radiation exposure [31,32]. Being known as sunscreen compounds, MAAs could also play a role in collagenase metabolism, a fact that never has been investigated before. Several different assay protocols are described in the literature for the identification of collagenase inhibitors from natural sources [29,33–35]. In many cases, bacterial collagenase from *C. histolyticum* was used because of its unique and extensive degradation ability on collagen compared to vertebrate collagenases [36]. Therefore, this type of enzyme was selected in our experiments. Substrates reported in the literature varied a lot, largely due to the applied detection mode (fluorescence vs. absorbance) [29,33]. However, none of the described assay procedures was validated, and thus the results of different studies are hardly comparable. By presenting a fully validated method for high-throughput screening purposes of collagenase inhibitors for the first time, we established a protocol that ensures reproducible results.

To the best of our knowledge, this is the first study on mycosporine-like amino acids serving as collagenase inhibitors. Even the observed effects on collagenase are moderate, MAAs, which are already known as sunscreen compounds, could possibly serve as anti-skin aging molecules. It is possible that they protect against wrinkled skin as a result of chronically aging or photoaging. Additionally, they may have beneficial effects in the prevention of skin cancer. All these aspects can serve as an interesting starting point for the development of new cosmetics or skin protective products. To date, over 30 different MAAs, mainly from marine sources, are known, which shows that possible applications are not limited to the compounds tested here. Our results indicate many options for the use of marine MAAs in the cosmetic or pharmaceutical industry.

Materials and Methods

Reagents and chemicals

Collagenase type V from *C. histolyticum* (EC 3.4.24.3), fluorogenic substrate peptide MMP-2 (MCA-Pro-Leu-Ala-Nva-DNP-Dap-Ala-Arg-NH₂), phosphoramidon disodium salt (purity > 97%), and the protease inhibitor 1,10-phenanthroline (purity > 99%) were purchased from Sigma-Aldrich. All other solvents used for isolation and extraction (methanol, butanol, hydrochloric acid, and acetonitrile) were of analytical grade and purchased from Merck. Black 96-well plates with flat bottoms came from BD Biosciences.

Fig. 6 Predicted binding modes of MAA to collagenase. Protein is shown as a green cartoon and semitransparent Van der Waals surface with the active site Zn^{2+} represented as a grey sphere. Side chain heavy atoms of metal coordinating amino acids are shown as sticks; pocket residues as thin lines. Hydrogen bonding and metal coordination are indicated as yellow dotted lines and marked with arrows. **A** Experimental binding mode of the peptide-derived inhibitor isoamylphosphonyl-Gly-Pro-Ala (PDB: 2Y6I). Ligand heavy atoms are shown in stick representation in atomic coloring with carbon in cyan. **B–D** Predicted binding modes of the MAA porphyra, shinorine, and palythine. (Color figure available online only.)

Biological material and extraction

For the isolation of MAAs, two commercially available algae, *Palmaria palmata* (Irish Seaweeds, LOT-Nr. 5391513420184) and *Porphyra* sp. (Asia Express Food, LOT-Nr. 120516) were used. The material was identified by microscopic means by one of the authors (A. Hartmann), and respective vouchers (2014-MAA-1 and 2014-MAA-2) are deposited at the Institute of Pharmacy, University of Innsbruck, Austria. Dried algal material was crushed to powder in a grinding mill prior to extraction using methanol/water (25:75) in an ultrasonic bath (Bandelin Sonorex 35 KHz) at 45 °C for 2 h [37]. After centrifugation at 3000 rpm for 10 min, the supernatant was collected and evaporated at 45 °C in a vacuum evaporator (Büchi). To obtain completely dried extracts, the resulting pasty liquid was transferred into a beaker and lyophilized (Heto power dry PL 6000, Thermo Fisher).

Isolation of MAAs

Dried extracts were dissolved in water and partitioned three times with 1-butanol to remove less polar components. The water fractions were combined, evaporated, and separated on an ion exchange resin (Dowex 50WX H^+ form, 100–200 mesh, Sigma-Aldrich) according to the protocol of Carignan et al. [38]. Briefly, the resin was placed in a glass column, the sample (aqueous solution) was applied, and the column was first rinsed with water. The elution of MAAs containing fractions was possible with 0.25 M HCl. To remove high salt concentrations, the obtained fractions were then applied on activated carbon cartridges (Supelco Envi-Carb, Sigma) and washed with water. Finally the

MAA-enriched fractions were eluted with pure methanol. Individual MAAs were isolated from these pre-purified extracts by semipreparative HPLC on a Dionex UltiMate 3000 preparative HPLC system (Thermo Fisher). The optimum separation was carried out on a Lichrosorb C18 100 Å column (200 mm × 10.00 mm; 7 µm) from Merck by using a mobile phase comprising 0.1 % acetic acid in water (A) and acetonitrile (B). The method was run isocratic for 30 min with 2 % mobile phase B. Then the column was washed for 10 min with 90 % B before being re-equilibrated for 15 min prior to the next injection. Detection was performed at 320 nm, the column was maintained at 20 °C, and the flow rate was set to 0.8 mL/min. The injected sample volume was 70 µL with a sample concentration of 25 mg/mL. After approx. 40–50 injections, 13.0 mg of porphyra and 8.5 mg shinorine (both with a purity of ≥ 95 %) were obtained from the pre-purified extract of *Porphyra* sp. Palythine (7.8 mg, purity ≥ 94 %) could be isolated from *P. palmata* using the same strategy. Detailed information on the isolation steps including HPLC chromatograms are provided as Supporting Information.

During separation and purification, the performance of each step was monitored by repeated HPLC-MS analysis, using an HP 1100 HPLC system from Agilent, coupled to an Esquire 3000 plus ion-trap mass spectrometer (Bruker). For analysis in an analytical scale, a Luna C-18 column (250 × 3.00 mm, 5 µm, Phenomenex) was used under the same conditions as described above, only the flow rate was set to 0.5 mL/min. MS spectra were obtained in alternating ESI modes by setting the temperature to 350 °C

Table 2 Collagenase inhibitory activity of the tested compounds.

Compound	IC ₅₀ (μM)
Shinorine	104.0 ± 3.7
Porphyrin	105.9 ± 2.3
Palythine	158.9 ± 3.2
Phosphoramidon	18.8 ± 1.6
1,10-Phenanthroline	238.1 ± 3.4

Values represent mean ± SD (n = 3)

and the nebulizer gas (nitrogen) to 40 psi, with a nebulizer flow (nitrogen) of 8 L/min.

Structural analysis of MAAs

NMR spectra were recorded at 25 °C on an Ultra-Shield 600 MHz instrument (Bruker) using the following experiments: ¹H- and ¹³C-NMR, two-dimensional correlation spectroscopy (2D COSY), heteronuclear multiple quantum coherence (HMQC), and heteronuclear multiple bond coherence (HMBC). All samples were dissolved in deuterated water, and tetramethylsilane (both from Euriso-Top) was used as an internal standard.

Collagenase inhibition assay

The fluorimetric assay was carried out in a 96-well microplate format on an Infinite F 200 pro microplate reader equipped with filter-based technology (Tecan). The general framework of the assay was taken from the literature [29]. In brief, the reaction was monitored at an excitation wavelength of 320 nm and 400 nm emission wavelength, and the positive controls phosphoramidon and 1,10-phenanthroline were used as described previously [16]. However, the assay was optimized in terms of enzyme and substrate concentrations, temperature, and incubation time. A peptide with an amino acid sequence of MCA-Pro-Leu-Ala-Nva-DNP-Dap-Ala-Arg-NH₂ was chosen as the substrate, which contains a fluorogenic residue (7-methoxycoumarin-4-yl acetic acid; MCA). If no inhibitor is present, the latter is released by the enzyme and a constant increase in fluorescence can be measured. Using the bacterial collagenase from *C. histolyticum* has several advantages. It cleaves not only the x-gly bond in collagen but also synthetic peptides and ECM, where it hydrolyses triple-helical collagen under both physiological and *in vitro* conditions [14, 15]. In favor of an HTS screening protocol, the volumes were kept to a minimum, obtaining a total final reaction volume of 100 μL, composed of 25 μL substrate, 25 μL enzyme, 25 μL buffer solution, and 25 μL sample/positive controls. The enzyme and substrate were dissolved in the reagent buffer (10 mM Tris-HCl; pH 7.3) in suitable concentrations. Both the enzyme and substrate were diluted from stock solutions to 100 μg/mL (initial) enzyme concentration and 55.55 μg/mL (initial) substrate concentration directly before use. Test samples were dissolved in water/DMSO, always maintaining a final DMSO concentration of 1% in each well. Buffer and sample solutions were added first, followed by the enzyme. This mixture was incubated for 10 min. Finally, the readout reaction was started by adding the fluorogenic substrate. A negative control was evaluated in the same manner by adding 25 μL 10 mM Tris-HCl buffer to the reaction instead of the test substance. For the determination the IC₅₀ values (MAAs and standard inhibitors) seven different concentrations were prepared in a serial dilution step. Each substance was tested in triplicate, with three replicates on each plate. In addition, a blank was taken for

each sample concentration to avoid false positive results due to a possible native fluorescence of the tested substances. The half maximal inhibitory concentration (IC₅₀) was calculated using the following formula:

$$\text{enzyme inhibition activity (\%)} = \frac{[\text{FU control} - \text{FU sample}]}{\text{FU control}} \times 100.$$

Supporting information

NMR shift values of the isolated substances porphyrin, shinorine, and palythine as well as the isolation protocol for *Porphyrin* sp. and docking scores for MAAs and phosphoramidon are available as Supporting Information.

Acknowledgements

This work was financially supported by the Austrian Science Fund (FWF), project P241680. J.E. Fuchs acknowledges funding from the UK Medical Research Council (grant MR/K020919/1).

Conflict of Interest

The authors declare no conflict of interest.

References

- Smith LT, Holbrook KA, Madri JA. Collagen types I, III, and V in human embryonic and fetal skin. *Am J Anat* 1986; 175: 507–521
- Woessner JF jr. The family of matrix metalloproteinases. Inhibition of matrix metalloproteinases. *Ann N Y Acad Sci* 1994; 732: 11–21
- Philips N, Conte J, Chen YJ, Natrajan P, Taw M, Keller T, Givant J, Tuason M, Dulaj L, Leonardi D, Gonzalez S. Beneficial regulation of matrix metalloproteinases and their inhibitors, fibrillar collagens and transforming growth factor-beta by *Polypodium leucotomos*, directly or in dermal fibroblasts, ultraviolet radiated fibroblasts, and melanoma cells. *Arch Dermatol Res* 2009; 301: 487–495
- Philips N, Keller T, Hendrix C, Hamilton S, Arena R, Tuason M, Gonzalez S. Regulation of the extracellular matrix remodeling by lutein in dermal fibroblasts, melanoma cells, and ultraviolet radiation exposed fibroblasts. *Arch Dermatol Res* 2007; 299: 373–379
- Philips N, Keller T, Holmes C. Reciprocal effects of ascorbate on cancer cell growth and the expression of matrix metalloproteinases and transforming growth factor-beta. *Cancer Lett* 2007; 256: 49–55
- Fisher GJ, Datta SC, Talwar HS, Wang ZQ, Varani J, Kang S, Voorhees JJ. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. *Nature* 1996; 379: 335–339
- Fisher GJ, Wang ZQ, Datta SC, Varani J, Kang S, Voorhees JJ. Pathophysiology of premature skin aging induced by ultraviolet light. *N Engl J Med* 1997; 337: 1419–1428
- Chung JH, Seo JY, Choi HR, Lee MK, Youn CS, Rhie G, Cho KH, Kim KH, Park KC, Eun HC. Modulation of skin collagen metabolism in aged and photoaged human skin *in vivo*. *J Invest Dermatol* 2001; 117: 1218–1224
- Wierzchacz C, Enis S, Kolander J, Gebhardt R. Differential inhibition of matrix metalloproteinases-2, -9, and -13 activities by selected anthraquinones. *Planta Med* 2009; 75: 327–329
- Park HY, Lim H, Kim HP, Kwon YS. Downregulation of matrix metalloproteinase-13 by the root extract of *Cyathula officinalis* Kuan and its constituents in IL-1β-treated chondrocytes. *Planta Med* 2011; 77: 1528–1530
- Lee SJ, Hong S, Yoo SH, Kim GY. Cyanidin-3-o-sambubioside from *Acanthopanax sessiliflorus* fruit inhibits metastasis by downregulating MMP-9 in breast cancer cells MDA-MB-231. *Planta Med* 2013; 79: 1636–1640
- Pallela R, Na-Young Y, Kim SK. Anti-photoaging and photoprotective compounds derived from marine organisms. *Mar Drugs* 2010; 8: 1189–1202
- β-Glucuronidase Assay. DyNA Quant™ Application Note 3. Amersham Biosciences. Available at https://www.gelifesciences.com/gehcls_

- images/GELS/Related%20Content/Files/1314716762536/litdoc 80623675_20110830181743.pdf. Accessed May 20, 2015
- 14 Kim YJ, Uyama H, Kobayashi S. Inhibition effects of (+)-catechin-aldehyde polycondensates on proteinases causing proteolytic degradation of extracellular matrix. *Biochem Biophys Res* 2004; 320: 256–261
 - 15 Thring TSA, Hili P, Naughton DP. Anti-collagenase, anti-elastase and anti-oxidant activities of extracts from 21 plants. *BMC Complement Altern Med* 2009; 9: 27
 - 16 Nsimba RY, Kikuzaki H, Konishi Y. Ecdysteroids act as inhibitors of calf skin collagenase and oxidative stress. *J Biochem Mol Toxicol* 2008; 22: 240–250
 - 17 La Barre S, Kornprobst JM. Outstanding marine molecules. Weinheim: Wiley-Blackwell; 2014: 387–430
 - 18 Klisch M, Richter P, Puchta R, Häder DP, Bauer W. The stereostructure of porphyrin-334: an experimental and calculational NMR investigation. Evidence for an efficient proton sponge. *Helv Chim Acta* 2007; 90: 488–511
 - 19 Zhang C, Kim SK. Matrix metalloproteinase inhibitors (MMPi) from marine natural products: the current situation and future prospects. *Mar Drugs* 2009; 7: 71–84
 - 20 Eckhard U, Schonauer E, Nuss D, Brandstetter H. Structure of collagenase G reveals a chew-and-digest mechanism of bacterial collagenolysis. *Nat Struct Mol Biol* 2011; 18: 1109–1139
 - 21 Labute P. Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures. *Proteins* 2009; 75: 187–205
 - 22 De Lano W. The Pymol Molecular Graphics System (Version1.5.0.2); 2008
 - 23 Fuchs JE, von Grafenstein S, Huber RG, Margreiter MA, Spitzer GM, Liedl KR. Cleavage entropy as quantitative measure of protease specificity. *PLoS Comput Biol* 2013; 9: e1003007
 - 24 Hu YB, Webb E, Singh J, Morgan B, Gainor A, Gordon JA, Siahaan TD. Rapid determination of substrate specificity of *Clostridium histolyticum* beta-collagenase using an immobilized peptide library. *J Biol Chem* 2002; 277: 8366–8371
 - 25 Huang XK, Chen S, Xu L, Liu YQ, Deb DK, Platanias LC, Bergan RC. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. *Cancer Res* 2005; 65: 3470–3478
 - 26 Rooprai HK, Kandaneeratchi A, Maidment SL, Christidou M, Trillo-Pazos G, Dexter DT, Rucklidge GJ, Widmer W, Pilkington GJ. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells *in vitro*. *Neuropathol Appl Neurobiol* 2001; 27: 29–39
 - 27 Kirszberg C, Esquenazi D, Alviano CS, Rumjanek VM. The effect of a catechin-rich extract of *Cocos nucifera* on lymphocytes proliferation. *Phytother Res* 2003; 17: 1054–1058
 - 28 Tang HJ, Martel K, Stribley J, Christman G. The effect of resveratrol on collagen expression in human uterine leiomyoma cells. *J Soc Gynecol Invest* 2006; 13: 70a–71a
 - 29 Moon HI, Kim TI, Cho HS, Kim EK. Identification of potential and selective collagenase, gelatinase inhibitors from *Crataegus pinnatifida*. *Bioorg Med Chem Lett* 2010; 20: 991–993
 - 30 Shick JM, Dunlap WC. Mycosporine-like amino acids and related gaduols: biosynthesis, accumulation, and UV-protective functions in aquatic organisms. *Annu Rev Physiol* 2002; 64: 223–262
 - 31 Aguilera J, Bishof K, Karsten U, Hanelt D, Wiencke C. Seasonal variation in ecophysiological patterns in macroalgae from an Arctic fjord. II. Pigment accumulation and biochemical defence systems against high light stress. *Mar Biol* 2002; 141: 603–604
 - 32 Llewellyn CA, Ains RL. Distribution and abundance of MAAs in 33 species of microalgae across 13 classes. *Mar Drugs* 2010; 8: 1273–1291
 - 33 Barrantes E, Guinea M. Inhibition of collagenase and metalloproteinases by aloins and aloe gel. *Life Sci* 2003; 72: 843–850
 - 34 Rennert B, Melzig MF. Free fatty acids inhibit the activity of *Clostridium histolyticum* collagenase and human neutrophil elastase. *Planta Med* 2002; 68: 767–769
 - 35 Teramachi F, Koyano T, Kowithayakorn T, Hayashi M, Komiyama K, Ishibashi M. Collagenase inhibitory quinic acid esters from *Ipomoea pes-caprae*. *J Nat Prod* 2005; 68: 794–796
 - 36 Seifter SEH. The collagenases. In: Boyer PD, editor. *The enzymes*, Vol. 3. New York: Academic Press; 1971: 649–697
 - 37 Tartarotti B, Sommaruga R. The effect of different methanol concentrations and temperatures on the extraction of mycosporine-like amino acids (MAAs) in algae and zooplankton. *Arch Hydrobiol* 2002; 154: 691–703
 - 38 Carignan MO, Cardozo KHM, Oliveira-Silva D, Colepicolo P, Carreto JL. Palythine-threonine, a major novel mycosporine-like amino acid (MAA) isolated from the hermatypic coral *Pocillopora capitata*. *J Photochem Photobiol B* 2009; 94: 191–200